These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
70 related articles for article (PubMed ID: 11723619)
1. [Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban]. Galli M; Vassanelli C Ital Heart J Suppl; 2001 Oct; 2(10):1127-9. PubMed ID: 11723619 [No Abstract] [Full Text] [Related]
2. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial. Sabatine MS; Morrow DA; Giugliano RP; Murphy SA; Demopoulos LA; DiBattiste PM; Weintraub WS; McCabe CH; Antman EM; Cannon CP; Braunwald E Circulation; 2004 Feb; 109(7):874-80. PubMed ID: 14757697 [TBL] [Abstract][Full Text] [Related]
3. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423 [TBL] [Abstract][Full Text] [Related]
5. Current strategies with high-dose tirofiban. Mukherjee D; Roffi M Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):275-80. PubMed ID: 17428156 [TBL] [Abstract][Full Text] [Related]
6. Platelet glycoprotein IIb/IIIa inhibitor therapy in non-ST segment elevation acute coronary syndromes. Elmouchi DA; Bates ER Minerva Cardioangiol; 2003 Oct; 51(5):547-60. PubMed ID: 14551523 [TBL] [Abstract][Full Text] [Related]
7. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study). Huynh T; Theroux P; Snapinn S; Wan Y; Am Heart J; 2003 Oct; 146(4):668-73. PubMed ID: 14564321 [TBL] [Abstract][Full Text] [Related]
8. Differential treatment benefit of platelet glycoprotein IIb/IIIa inhibition with percutaneous coronary intervention versus medical therapy for acute coronary syndromes: exploration of methods. Pieper KS; Tsiatis AA; Davidian M; Hasselblad V; Kleiman NS; Boersma E; Chang WC; Griffin J; Armstrong PW; Califf RM; Harrington RA Circulation; 2004 Feb; 109(5):641-6. PubMed ID: 14769687 [TBL] [Abstract][Full Text] [Related]
9. The evolving role of glycoprotein IIb/IIIa inhibitor therapy in contemporary care of acute coronary syndrome patients. Tricoci P; Peterson ED J Interv Cardiol; 2006 Oct; 19(5):449-55. PubMed ID: 17020570 [TBL] [Abstract][Full Text] [Related]
11. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes. Bolognese L Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721 [TBL] [Abstract][Full Text] [Related]